Categories
Change Password!
Reset Password!
Tegoprazan 50 mg offers rapid, consistent, and superior healing benefits in erosive esophagitis compared to lansoprazole 30 mg.
A multicenter clinical trial has revealed that tegoprazan, a novel potassium-competitive acid blocker (P-CAB), is not only non-inferior but also superior to lansoprazole, a conventional proton pump inhibitor (PPI), in healing erosive esophagitis (EE) within 4 weeks. The findings also highlight tegoprazan’s potential for faster mucosal recovery and symptom relief. This randomized trial enrolled 218 patients with endoscopically confirmed EE, classified under the Los Angeles (LA) grading system (A–D).
Volunteers were randomly assigned to get either tegoprazan 50 mg or lansoprazole 30 mg once daily for 4 weeks. The key endpoint was the cumulative rate of healed EE up to week 4, as assessed via endoscopy. The secondary endpoints encompassed healing rates at week 2, symptom improvement, and analysis of the impact of CYP2C19 genotypes on treatment outcomes. Safety and tolerability were also tracked. A total of 103 patients in the tegoprazan group and 109 patients in the lansoprazole group were included in the full analysis.
Both medications were well-tolerated, with no vital differences in adverse events. Thus, tegoprazan is not only non-inferior but also superior to lansoprazole for healing EE within 4 weeks. It also promotes faster mucosal recovery and consistent results across genetic profiles.
Neurogastroenterology & Motility
Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial
Cheol Min Shin et al.
Comments (0)